News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
281,574 Results
Type
Article (14895)
Company Profile (299)
Press Release (266374)
Multimedia
Podcasts (78)
Webinars (11)
Section
Business (79839)
Career Advice (162)
Deals (13336)
Drug Delivery (39)
Drug Development (50696)
Employer Resources (31)
FDA (5836)
Job Trends (5168)
News (145076)
Policy (10071)
Tag
2027 Biotech Bay Standard (1)
2027 Genetown Elite (1)
2027 Genetown Standard (1)
2027 Pharm Country Standard (2)
Academia (920)
Accelerated approval (19)
Adcomms (14)
Allergies (81)
Alliances (21764)
ALS (124)
Alzheimer's disease (1030)
Antibody-drug conjugate (ADC) (241)
Approvals (6030)
Artificial intelligence (258)
Autoimmune disease (110)
Automation (9)
Bankruptcy (105)
Best Places to Work (4561)
BIOSECURE Act (6)
Biosimilars (100)
Biotechnology (230)
Bladder cancer (101)
Brain cancer (45)
Breast cancer (343)
Cancer (3127)
Cardiovascular disease (237)
Career advice (147)
Career pathing (7)
CAR-T (217)
CDC (5)
Cell therapy (563)
Cervical cancer (14)
Clinical research (43663)
Collaboration (1148)
Company closure (2)
Compensation (591)
Complete response letters (39)
COVID-19 (1100)
CRISPR (86)
C-suite (550)
Cystic fibrosis (112)
Data (4316)
Denatured (15)
Depression (92)
Diabetes (254)
Diagnostics (1378)
Digital health (10)
Diversity (5)
Diversity, equity & inclusion (9)
Drug discovery (187)
Drug pricing (48)
Drug shortages (3)
Duchenne muscular dystrophy (213)
Earnings (31642)
Editorial (25)
Employer branding (4)
Employer resources (29)
Events (51657)
Executive appointments (621)
FDA (7583)
Fibrodysplasia Ossificans Progressiva (5)
Friedreich's ataxia (9)
Frontotemporal dementia (22)
Funding (980)
Gene editing (182)
Generative AI (21)
Gene therapy (486)
GLP-1 (504)
Government (1147)
Grass and pollen (3)
Guidances (166)
Healthcare (6612)
HIV (18)
Huntington's disease (43)
IgA nephropathy (74)
Immunology and inflammation (190)
Immuno-oncology (39)
Indications (66)
Infectious disease (1204)
Inflammatory bowel disease (155)
Inflation Reduction Act (10)
Influenza (38)
Intellectual property (166)
Interviews (18)
IPO (7345)
IRA (12)
Job creations (867)
Job search strategy (129)
JPM (40)
Kidney cancer (9)
Labor market (22)
Layoffs (243)
Leadership (9)
Legal (1400)
Liver cancer (41)
Longevity (11)
Lung cancer (419)
Lymphoma (248)
Machine learning (24)
Management (7)
Manufacturing (375)
MASH (130)
Medical device (2662)
Medtech (2671)
Mergers & acquisitions (6614)
Metabolic disorders (724)
Multiple sclerosis (102)
NASH (13)
Neurodegenerative disease (229)
Neuropsychiatric disorders (70)
Neuroscience (1949)
Neurotech (1)
NextGen: Class of 2026 (2034)
Non-profit (865)
Now hiring (30)
Obesity (329)
Opinion (125)
Ovarian cancer (131)
Pain (102)
Pancreatic cancer (161)
Parkinson's disease (232)
Partnered (12)
Patents (301)
Patient recruitment (327)
Peanut (43)
People (26652)
Pharmaceutical (44)
Pharmacy benefit managers (6)
Phase 1 (15473)
Phase 2 (20285)
Phase 3 (12819)
Pipeline (3239)
Policy (90)
Postmarket research (853)
Preclinical (6535)
Press Release (30)
Prostate cancer (145)
Psychedelics (50)
Radiopharmaceuticals (238)
Rare diseases (647)
Real estate (1447)
Recruiting (12)
Regulatory (9891)
Reports (19)
Research institute (971)
Resumes & cover letters (18)
Rett syndrome (24)
RNA editing (21)
RSV (16)
Schizophrenia (123)
Series A (182)
Series B (135)
Service/supplier (1)
Sickle cell disease (77)
Special edition (18)
Spinal muscular atrophy (119)
Sponsored (15)
Startups (2005)
State (1)
Stomach cancer (5)
Supply chain (32)
Tariffs (18)
The Weekly (62)
Vaccines (333)
Venture capital (69)
Weight loss (173)
Women's health (25)
Worklife (2)
Date
Last 7 days (343)
Last 30 days (1117)
Last 365 days (17797)
2026 (1652)
2025 (18098)
2024 (20543)
2023 (22414)
2022 (26822)
2021 (27806)
2020 (23356)
2019 (16224)
2018 (11740)
2017 (13745)
2016 (11839)
2015 (14349)
2014 (10392)
2013 (7484)
2012 (7534)
2011 (7614)
2010 (7428)
Location
Africa (154)
Alabama (65)
Alaska (2)
Arizona (71)
Arkansas (5)
Asia (18250)
Australia (3110)
California (7074)
Canada (1837)
China (772)
Colorado (246)
Connecticut (252)
Delaware (235)
Europe (39157)
Florida (902)
Georgia (209)
Hawaii (2)
Idaho (17)
Illinois (395)
India (35)
Indiana (160)
Iowa (8)
Japan (222)
Kansas (80)
Kentucky (9)
Louisiana (7)
Maine (11)
Maryland (736)
Massachusetts (5578)
Michigan (110)
Minnesota (247)
Mississippi (3)
Missouri (32)
Montana (16)
Nebraska (5)
Nevada (32)
New Hampshire (21)
New Jersey (1645)
New Mexico (13)
New York (1760)
North Carolina (825)
North Dakota (6)
Northern California (3473)
Ohio (177)
Oklahoma (11)
Oregon (24)
Pennsylvania (1276)
Puerto Rico (9)
Rhode Island (25)
South America (215)
South Carolina (9)
Southern California (2806)
Tennessee (40)
Texas (904)
United States (23320)
Utah (96)
Virginia (136)
Washington D.C. (37)
Washington State (592)
West Virginia (1)
Wisconsin (45)
281,574 Results for "tessera therapeutics".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Tessera Therapeutics Announces FDA Clearance of IND Application for its Lead In Vivo Gene Editing Program TSRA-196 for AATD
January 12, 2026
·
3 min read
Press Releases
Tessera Therapeutics Announces Chief Financial Officer (CFO) Transition and Appointment of Kathy Bergsteinsson as CFO
December 10, 2025
·
3 min read
Press Releases
UPDATE -- Tessera Therapeutics Announces Chief Financial Officer (CFO) Transition and Appointment of Kathy Bergsteinsson as CFO
December 10, 2025
·
3 min read
Press Releases
Regeneron and Tessera Therapeutics to Jointly Develop TSRA-196, an Investigational Gene Editing Therapy for Alpha-1 Antitrypsin Deficiency (AATD)
December 2, 2025
·
12 min read
Gene editing
Regeneron Makes $275M Gene Editing Play With Tessera Partnership Targeting AATD
The centerpiece of the deal is the
in vivo
editor TSRA-196, which in preclinical studies has shown robust editing at SERPINA1, the locus linked to alpha-1 antitrypsin deficiency.
December 1, 2025
·
1 min read
·
Tristan Manalac
Press Releases
Tessera Therapeutics Showcases New Preclinical Data Demonstrating Progress of In Vivo Programs for Sickle Cell Disease and T Cell Therapies at the 67th American Society of Hematology Annual Meeting
December 8, 2025
·
5 min read
Press Releases
Tessera Therapeutics Awarded up to $41.3 Million from ARPA-H to Advance In Vivo CAR-T Therapies
October 9, 2025
·
3 min read
Press Releases
Tessera Therapeutics to Present New Preclinical Data From In Vivo Programs for Sickle Cell Disease and T Cell Therapies at the 67th American Society of Hematology Annual Meeting
November 4, 2025
·
2 min read
Press Releases
Tessera Therapeutics Features New Preclinical Data Demonstrating Progress Across its In Vivo Gene Writing™ Programs and Delivery Platform at the American Society of Gene and Cell Therapy 28th Annual Meeting
May 19, 2025
·
7 min read
Press Releases
Tessera Therapeutics to Present New Data Across Preclinical Programs for its Gene Writing™ and Delivery Platforms at the American Society of Gene and Cell Therapy 28th Annual Meeting
April 28, 2025
·
3 min read
1 of 28,158
Next
